The Effect of Esomeprazole on Type 2 Diabetes

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to prospectively investigate the effects of esomeprazole on glycaemic control in patients with type 2 diabetes mellitus. The investigators also aimed to associate this effect with gastrin levels. Thirty-two type 2 diabetes mellitus objects were recruited into intervention (n=16) and control (n=16) groups. The participants in the intervention group were prescribed 40 mg of esomeprazole treatment for three months. At the beginning of the study and at month 3, HbA1c level (%) and gastrin levels (pmol/L) of participants were assessed. Then the baseline and 3rd month data of groups were compared.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baskent University Ankara Hospital
• Treatments: Esomeprazole; Gastrins

Criteria

Inclusion Criteria:

• All the participants that has a diagnosis of T2DM and had at least 1-year follow-up in Endocrinology outpatient clinic.

• All the study participants were chosen from regulated diabetic subjects whose diabetes treatment were not amended.

• In the intervention group, all participants had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis

• The control group consisted of without gastric complaints, thus who did not receive PPI drugs.

Exclusion Criteria:

• We excluded any cases needing revision in their treatment strategies due to ethical issues.

• Subjects, on pioglitazone and incretin-based therapies;

• Subjects with a history of gastrointestinal surgery, liver or kidney disease, diabetic macro- or microvascular complications;

• Subjects who are lactating or pregnant

• Subjects on any PPI treatment or had a history of PPI use in a 3 months period before the study, were excluded.